- 2023 Clinical Practice Guidelines for Diabetes: Recommendations for Pharmacological Treatment of Type 2 Diabetes
-
Noh J
- KMID: 2546629
- J Korean Diabetes.
- 2023 Sep;24(3):127-134.
- doi: 10.4093/jkd.2023.24.3.127
The 2023 clinical practice guidelines for diabetes in Korea are reviewed and updated biennially by the Committee of Clinical Practice Guidelines of the Korean Diabetes Association based on the latest... -
- CITED
-
- Close
- SHARE
-
- Close
- 2023 Clinical Practice Guidelines for Diabetes
-
Moon MK
- KMID: 2546628
- J Korean Diabetes.
- 2023 Sep;24(3):120-126.
- doi: 10.4093/jkd.2023.24.3.120
The Committee on Clinical Practice Guidelines of the Korean Diabetes Association updated the previous clinical practice guidelines for Korean adults with diabetes and prediabetes and published the eighth edition in... -
- CITED
-
- Close
- SHARE
-
- Close
- 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
-
Yang YS
- KMID: 2546630
- J Korean Diabetes.
- 2023 Sep;24(3):135-140.
- doi: 10.4093/jkd.2023.24.3.135
To prevent cardiovascular disease (CVD), which is one of the ultimate goals in the management of patients with diabetes, it is important to control not only hyperglycemia, but also modifiable... -
- CITED
-
- Close
- SHARE
-
- Close
- 2023 Clinical Practice Guidelines for Diabetes: Continuous Glucose Monitoring and Insulin Pumps
-
Jin SM
- KMID: 2546631
- J Korean Diabetes.
- 2023 Sep;24(3):141-147.
- doi: 10.4093/jkd.2023.24.3.141
With the expanding use of continuous glucose monitoring (CGM) and insulin pumps worldwide, several international guidelines dedicated to diabetes technology have been developed. Recently, the Korean Diabetes Association released a... -
- CITED
-
- Close
- SHARE
-
- Close
- Characteristics of the Latest Therapeutic Agent for Diabetes
-
Yun N
- KMID: 2546632
- J Korean Diabetes.
- 2023 Sep;24(3):148-153.
- doi: 10.4093/jkd.2023.24.3.148
The latest therapeutic agent for diabetes is characterized by a longer lasting blood glucose control effect than existing treatments and stable blood glucose control. In addition, it has the advantage... -
- CITED
-
- Close
- SHARE
-
- Close
- Trends and Effects in Evidence-Based Psycho-Social Interventions for Patients with Diabetes
-
Lim Jw
- KMID: 2546634
- J Korean Diabetes.
- 2023 Sep;24(3):164-171.
- doi: 10.4093/jkd.2023.24.3.164
The purpose of this study is to explore psycho-social interventions for patients with diabetes and to suggest the effects of such interventions based on findings from systematic review and meta-analysis.... -
- CITED
-
- Close
- SHARE
-
- Close
- Approach to Fatty Liver Disease in Patients with Type 2 Diabetes
-
Bae JC
- KMID: 2546626
- J Korean Diabetes.
- 2023 Sep;24(3):107-110.
- doi: 10.4093/jkd.2023.24.3.107
Type 2 diabetes is a major risk factor for development and progression of non-alcoholic fatty liver disease (NAFLD). Fatty liver is prevalent in people with type 2 diabetes, and overweight... -
- CITED
-
- Close
- SHARE
-
- Close
- Diabetes and Dietary Fats
-
Cho JW
- KMID: 2546633
- J Korean Diabetes.
- 2023 Sep;24(3):154-163.
- doi: 10.4093/jkd.2023.24.3.154
Fats are important nutrients that supply energy and help to regulate the processes of the human body. The proportion of fat in the energy intake of Koreans, as well as... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Dyslipidemia in Patients with Diabetes Mellitus
-
Lee KA
- KMID: 2546627
- J Korean Diabetes.
- 2023 Sep;24(3):111-119.
- doi: 10.4093/jkd.2023.24.3.111
Most patients with diabetes mellitus (DM) have dyslipidemia, which is characterized by increased triglycerides, decreased high-density lipoprotein cholesterol, and increased small dense low-density lipoprotein cholesterol (LDL-C). Dyslipidemia is an important... -
- CITED
-
- Close
- SHARE
-
- Close
